Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Anticancer Research

• Publication date

  1992-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 1352440
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cathepsin D and prognosis in breast cancer.

  1990cited by this paper
• HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.

  1990cited by this paper
• HER-2/neu oncogene expression and proliferation in breast cancers.

  1990cited by this paper
• Image cytometry of aneuploidy, growth fraction (MoAb Ki-67) and hormone receptors (ER, PR) immunocytochemical assays in breast carcinomas.

  1990cited by this paper
• Prediction of relapse and survival in breast cancer patients by pS2 protein status.

  1990cited by this paper
• Type IV collagen immunostaining and computerized image analysis (SAMBA) in breast and endometrial disorders

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Immunocytochemical assays in human endometrial carcinomas: a multiparametric computerized analysis and comparison with nonmalignant changes.

  1989cited by this paper
• Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance

  1989cited by this paper
• Cathepsin D: an independent prognostic factor for metastasis of breast cancer.

  1989cited by this paper
• Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data.

  1988cited by this paper
• Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections.

  1988cited by this paper
• Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in nonmalignant and malignant breast disorders.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Flow cytometric analysis for assessing the malignant potential of breast cancer

  1987cited by this paper
• Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

  1987cited by this paper
• Cytometry of breast carcinoma: significance of ploïdy balance and proliferation index.

  1987cited by this paper
• Immunohistochemical detection of laminin in 98 human breast carcinomas: a light and electron microscopic study.

  1986cited by this paper
• Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.

  1986cited by this paper
• Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas.

  1986cited by this paper
• Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients.

  1985cited by this paper
• Inflammatory tumors of the human breast: determination of estrogen and progesterone receptors.

  1984cited by this paper
• Carcinoembryonic Antigen (CEA) and Carbohydrate Determinant 19–9 (CA 19–9) Localization in 121 Primary and Metastatic Ovarian Tumors: An Immunohistochemical Study with the Use of Monoclonal Antibodies

  1982cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper
• Prognosis in Carcinoma of the Breast

  1950cited by this paper

• Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study

  2024cites this paper
• Inflammatory breast cancer biomarkers and biology.

  2024cites this paper
• The Significance of Skin Oedema in Locally Advanced Breast Cancer and Its Response to Neoadjuvant Chemotherapy

  2023cites this paper
• Forecasting factors and outcomes in hawkish inflammatory breast carcinoma - A single center data exploration.

  2022cites this paper
• BCTT_A_231502 153..163

  2020cites this paper
• Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis

  2020cites this paper
• Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility

  2020cites this paper
• Inflammatory Breast Cancer: A Panoramic Overview

  2018cites this paper
• Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.

  2018cites this paper
• Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy.

  2018cites this paper
• Inflammatory breast cancer biology: the tumour microenvironment is key

  2018cites this paper
• Pathology of Inflammatory Breast Cancer

  2013cites this paper
• Inflammatory Breast Cancer - Does the Confirmation of Dermal Lymphatic Invasion Predict the Worst Outcome?

  2012cites this paper
• Molecules That Drive the Invasion and Metastasis of Inflammatory Breast Cancer

  2012cites this paper
• International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

  2011cites this paper
• Inflammatory breast cancer.

  2011cites this paper
• Inflammatory Breast Cancer: The Disease, the Biology, the Treatment

  2010cites this paper
• Metastasis of canine inflammatory versus non-inflammatory mammary tumours.

  2010cites this paper
• Inflammatory breast cancer.

  2009cites this paper
• Histological, Immunohistological, and Ultrastructural Description of Vasculogenic Mimicry in Canine Mammary Cancer

  2009cites this paper
• Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype.

  2008cites this paper
• Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis.

  2008cites this paper
• Biology of Inflammatory Breast Cancer

  2008cites this paper
• Defining the molecular biology of inflammatory breast cancer.

  2008cites this paper
• Comparison of Inflammatory Breast Cancer and Noninflammatory Breast Cancer in Western Turkey

  2008cites this paper
• Epidemiology of Inflammatory Breast Cancer (IBC)

  2006cites this paper
• Benigne und maligne Tumoren der Mamma

  2006cites this paper
• Occult inflammatory breast cancer: review of clinical, mammographic, US and pathologic signs.

  2005cites this paper
• Review Update on inflammatory breast cancer

  2005cites this paper
• Update on inflammatory breast cancer

  2005cites this paper
• Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’

  2004cites this paper
• Cathepsin D in primary breast carcinoma: Adverse prognosis is associated with expression of cathepsin D in stromal cells

  2004cites this paper
• Matrix-degrading proteases in hormone-dependent breast cancer

  2004cites this paper
• Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer

  2004cites this paper
• [Inflammatory breast carcinoma: towards molecular characterization?].

  2003cites this paper
• HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

  2002cites this paper
• Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999).

  2001cites this paper
• Case Control Study of Prognostic Markers and Disease Outcome in Inflammatory Carcinoma Breast: A Unique Clinical Experience

  2001cites this paper
• Maligne Tumoren der Mamma

  2001cites this paper
• Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6

  1999cites this paper
• Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens.

  1997cites this paper
• Relevance of multiple biological parameters in breast cancer prognosis

  1996cites this paper
• Inflammatory breast cancer: the evolution of multimodality treatment strategies.

  1996cites this paper
• Cathepsins D and B in breast cancer.

  1996cites this paper
• Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition?

  1995cites this paper
• Biological and clinical relevance of proliferative activity in inflammatory breast-cancer.

  1995cites this paper
• Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay.

  1994cites this paper
• Analysis of breast-tissue cathepsin-d isoforms from patients with breast-cancer, benign breast disease and from normal controls.

  1994cites this paper
• Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cites this paper
• [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].

  1994cites this paper
• Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.

  1993cites this paper
• pS2 protein in gastric carcinoma and normal gastric mucosa: Association with clinicopathological parameters and patient survival

  1993cites this paper
• Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.

  1993cites this paper
• Trefoil peptides: a newly recognized family of epithelial mucin-associated molecules.

  1993cites this paper